SCHEMBL31335307

SCHEMBL31335307

O=C(Cc1ccc(Br)cc1)N1CCCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
NPC1 O15118 2/20 1.00
ALDH1A1 P00352 4/20 0.63
MAPT P10636 4/20 0.63
HTT P42858 4/20 0.62
GAA P10253 1/20 0.62
ALOX12 P18054 1/20 0.62
LMNA P02545 2/20 0.61
RAB9A P51151 1/20 0.57
KDM4E B2RXH2 1/20 0.56
POLB P06746 1/20 0.55
GPR183 P32249 2/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
HRH3 Q9Y5N1 1/20 0.54
ECE2 P0DPD6 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2646798 0.98 HPGD (0.96) HPGDSMN1; SMN2NPC1ALDH1A1MAPT
SCHEMBL15301122 0.95 HPGD (0.90) HPGDSMN1; SMN2NPC1ALDH1A1MAPT
SCHEMBL13858035 0.84 SMN1; SMN2 (0.73) HPGDSMN1; SMN2NPC1ALDH1A1MAPT
SCHEMBL2240974 0.84 SMN1; SMN2 (0.72) HPGDSMN1; SMN2NPC1ALDH1A1MAPT
SCHEMBL2236040 0.84 SMN1; SMN2 (0.72) HPGDSMN1; SMN2NPC1ALDH1A1HTT
SCHEMBL2376378 0.83 SMN1; SMN2 (0.71) HPGDSMN1; SMN2NPC1ALDH1A1MAPT
SCHEMBL2798761 0.83 L3MBTL1 (0.72) HPGDSMN1; SMN2NPC1ALDH1A1MAPT
SCHEMBL9528958 0.82 HPGD (0.70) HPGDSMN1; SMN2NPC1ALDH1A1MAPT
SCHEMBL3170967 0.82 SMN1; SMN2 (0.70) HPGDSMN1; SMN2NPC1ALDH1A1MAPT
SCHEMBL12082384 0.82 SMN1; SMN2 (0.70) HPGDSMN1; SMN2NPC1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719605-A1 CHEMICAL COMPOUNDS AND USES THEREOF GlaxoSmithKline Intellectual Property (No.4) Limited (GB) 2026-04-08 EP disclosed
US-20260015321-A1 CHEMICAL COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED (GB) 2026-01-15 US disclosed
EP-4663630-A1 NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR LG Chem, Ltd. (KR) 2025-12-17 EP disclosed
WO-2024246862-A1 CHEMICAL COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED (GB) 2024-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015321-A1 CHEMICAL COMPOUNDS AND USES THEREOF WRN, MSH2, MSH6 HPGD 770/4885SMN1; SMN2 606/4885NPC1 2991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.